Veracyte, Inc. (VCYT) Stock Price & Analysis
Veracyte, Inc. (VCYT) rose 4.17% to USD 49.24 as of June 10, 2026 at 03:11 UTC, according to Nexqual real-time market data.
VCYT last closed at USD 47.27; the session ranged USD 46.89–49.32 on volume of 986,829 shares. Market capitalization is $3.93B, with a 52-week range of USD 22.61–50.71 (NGM). Source: Nexqual, June 10, 2026 at 03:11 UTC.
Key Statistics (as of June 10, 2026 at 03:11 UTC)
| Price | USD 49.24 |
|---|---|
| Change | ▲ 4.17% (up) |
| Previous Close | USD 47.27 |
| Open | USD 47.95 |
| Day Range | USD 46.89 – 49.32 |
| 52-Week Range | USD 22.61 – 50.71 |
| Volume | 986,829 shares |
| Market Cap | $3.93B |
| Exchange | NGM |
Technical Analysis (VCYT)
Nexqual's technical model rates VCYT "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:11 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 67.53 (neutral) |
| vs SMA50 | Above (USD 38.26) |
| MACD | 3.17 (positive) |
Analyst Ratings (VCYT)
Wall Street analysts rate VCYT "Buy" based on 10 analysts, with a mean price target of USD 49.1 (range USD 37–57), per Nexqual as of June 10, 2026 at 03:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 49.1 |
| High Target | USD 57 |
| Low Target | USD 37 |
| Buy / Hold / Sell | 9 / 1 / 1 |
Earnings (VCYT)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.43 |
| Revenue Estimate | $144.43M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.52 vs est 0.33 ▲ beat |
| 2025-12-31 | USD 0.53 vs est 0.41 ▲ beat |
| 2025-09-30 | USD 0.51 vs est 0.32 ▲ beat |
| 2025-06-30 | USD 0.44 vs est 0.3 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
Financials & Fundamentals (VCYT)
| Total Revenue | $541.74M |
|---|---|
| Revenue Growth (YoY) | +21.50% |
| Gross Margin | +72.91% |
| Operating Margin | +16.28% |
| Profit Margin | +16.25% |
| ROE | +6.93% |
| Debt / Equity | 2.93 |
| Current Ratio | 9.31 |
| Total Cash | $439.06M |
| Total Debt | $39.33M |
| Free Cash Flow | $104.51M |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
Financial Health Score (VCYT)
Nexqual rates Veracyte, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 03:11 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 73%, operating 16% |
| Balance Sheet | Strong — $439M cash vs $39M debt, net cash position |
| Cash Flow | Strong — FCF $105M, 20% margin |
| Efficiency | Mixed — ROE 7%, ROA 3.8% |
Ownership (VCYT)
| Insider Ownership | +0.49% |
|---|---|
| Institutional Ownership | +113.28% |
| Shares Outstanding | 79.79M |
| Float | 79.37M |
| Short % of Float | +10.90% |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
Leadership (VCYT)
Veracyte, Inc. is led by Marc A. Stapley (age 55), CEO & Director, per Nexqual as of June 10, 2026 at 03:11 UTC.
| CEO & Director | Marc A. Stapley (age 55) |
|---|---|
| Executive VP & CFO | Rebecca Chambers (age 47) |
| Chief Scientific & Medical Officer | Phillip G. Febbo (age 59) |
| Senior Vice President of Global Operations | Keith Gligorich |
| Director of Investor Relations | Kelly Gura |
Major Backers & Investors (VCYT)
Notable institutional backers of Veracyte, Inc. include FMR, LLC, Artisan Partners Limited Partnership, ARK Invest, according to Nexqual as of June 10, 2026 at 03:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 9.73% |
| Artisan Partners Limited Partnership | 6.89% |
| ARK Invest | 6.11% |
| Fidelity | 3.29% |
| Wellington Management | 3.21% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 3.03% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 24.86% |
| Vanguard Group | 17.3% |
| State Street | 9.06% |
| Dimensional Fund Advisors | 3.61% |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
From Veracyte, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We rely on sole suppliers for critical supply of reagents, equipment and other materials and services that we use to perform our CLIA tests as well as to satisfy demand for our Prosigna test kits, service kits and service on the nCounter Analysis System.
- Certain of our products are regulated as IVD MDs, including Prosigna and the nCounter Analysis System.
- While we have developed alternate sourcing strategies for many materials, vendors and service providers, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDNA | CareDx, Inc. | USD 22.75 | ▲ 2.25% |
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| FATE | Fate Therapeutics, Inc. | USD 1.9 | ▼ 4.04% |
| TXG | 10x Genomics, Inc. | USD 30.59 | ▼ 1.45% |
| PSNL | Personalis, Inc. | USD 9.75 | ▼ 9.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:11 UTC. This page is informational and not investment advice.